MX2020003662A - Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona. - Google Patents

Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona.

Info

Publication number
MX2020003662A
MX2020003662A MX2020003662A MX2020003662A MX2020003662A MX 2020003662 A MX2020003662 A MX 2020003662A MX 2020003662 A MX2020003662 A MX 2020003662A MX 2020003662 A MX2020003662 A MX 2020003662A MX 2020003662 A MX2020003662 A MX 2020003662A
Authority
MX
Mexico
Prior art keywords
guanfacine
transdermal
therapeutic system
hybrid polymer
acrylic hybrid
Prior art date
Application number
MX2020003662A
Other languages
English (en)
Inventor
Marco Emgenbroich
Eva - Marie Prinz
Elke Klein
Heike Kluth
Xavier Thomas
Linda Sue Nartker
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of MX2020003662A publication Critical patent/MX2020003662A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a un sistema terapéutico transdérmico para la administración transdérmica de guanfacina, que comprende una estructura de capa que contiene guanfacina, dicha estructura de capa que contiene guanfacina comprende: A) una capa de refuerzo; y B) una capa que contiene guanfacina en donde el sistema terapéutico transdérmico comprende al menos un polímero híbrido acrílico de silicona.
MX2020003662A 2017-10-11 2018-10-11 Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona. MX2020003662A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570748P 2017-10-11 2017-10-11
EP17205538 2017-12-05
PCT/EP2018/077790 WO2019072996A1 (en) 2017-10-11 2018-10-11 TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL GUANFACIN ADMINISTRATION COMPRISING A SILICONE-ACRYLIC HYBRID POLYMER

Publications (1)

Publication Number Publication Date
MX2020003662A true MX2020003662A (es) 2020-10-01

Family

ID=63878659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003662A MX2020003662A (es) 2017-10-11 2018-10-11 Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona.

Country Status (13)

Country Link
US (1) US20200397714A1 (es)
EP (1) EP3694497B1 (es)
JP (2) JP2020536878A (es)
KR (1) KR20200070307A (es)
CN (1) CN111491621A (es)
AU (1) AU2018348769A1 (es)
BR (1) BR112020007093A2 (es)
CA (1) CA3079694A1 (es)
ES (1) ES2954714T3 (es)
MX (1) MX2020003662A (es)
RU (1) RU2020115559A (es)
TW (1) TW201924663A (es)
WO (1) WO2019072996A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019072997A1 (en) 2017-10-11 2019-04-18 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL GUANFACIN ADMINISTRATION COMPRISING A SILICONE POLYMER
CN113648285B (zh) * 2021-07-15 2022-11-11 南京海纳医药科技股份有限公司 一种盐酸胍法辛膜控释片剂及其制备方法
DE102021128911A1 (de) * 2021-11-05 2023-05-11 Lts Lohmann Therapie-Systeme Ag. Diclofenac enthaltendes tts mit dimethylpropylenharnstoff

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028431A (en) * 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
JPH07145048A (ja) * 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 医療用貼付剤
US8124689B2 (en) * 2006-06-06 2012-02-28 Dow Corning Corporation Silicone acrylate hybride composition and method of making same
RU2544702C2 (ru) 2009-04-24 2015-03-20 Хенкель Корпорейшн Клеи на основе силикон-акрилового гибридного полимера
TWI505819B (zh) * 2010-07-29 2015-11-01 Hisamitsu Pharmaceutical Co 醫療用貼附劑
JP2013139554A (ja) * 2011-11-29 2013-07-18 Dow Corning Corp シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法
US20150342899A1 (en) * 2012-12-28 2015-12-03 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine and clonidine
MX370376B (es) * 2014-07-31 2019-12-11 Noven Pharma Polímeros acrílicos que contienen silicona para composiciones para suministro de fármacos transdérmicos.
KR102048682B1 (ko) 2015-02-09 2019-11-27 다우 실리콘즈 코포레이션 다중상 실리콘 아크릴 하이브리드 점탄성 조성물 및 이의 제조 방법
WO2019072997A1 (en) * 2017-10-11 2019-04-18 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL GUANFACIN ADMINISTRATION COMPRISING A SILICONE POLYMER

Also Published As

Publication number Publication date
EP3694497B1 (en) 2023-06-07
EP3694497A1 (en) 2020-08-19
CN111491621A (zh) 2020-08-04
CA3079694A1 (en) 2019-04-18
BR112020007093A2 (pt) 2020-09-24
AU2018348769A1 (en) 2020-04-16
JP2020536878A (ja) 2020-12-17
JP2023116688A (ja) 2023-08-22
EP3694497C0 (en) 2023-06-07
ES2954714T3 (es) 2023-11-23
WO2019072996A1 (en) 2019-04-18
KR20200070307A (ko) 2020-06-17
RU2020115559A (ru) 2021-11-12
TW201924663A (zh) 2019-07-01
US20200397714A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
MX2020003667A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona.
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
SV2016005214A (es) Sistema de administración farmacológico
ECSP15040888A (es) PROTEÍNAS DE UNIÓN ESPECÍFICAS DUALES DIRIGIDAS CONTRA TNF alfa
PE20181155A1 (es) Composiciones que comprenden cepas bacterianas
CO2018000809A2 (es) Anticuerpos para cd40
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
BR112014024494A2 (pt) dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
GT201500011A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
MX2020003662A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CL2013000423A1 (es) Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno.
EA201291158A1 (ru) Комбинированные вакцины с синтетическими наноносителями
UY33756A (es) Compuesto biciclico
CU20150018A7 (es) Composición para el tratamiento de la infección por hepatitis b o coinfección por hepatitis b/hepatitis d
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
BR112016012615A8 (pt) sistemas, e kit
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
BR112017005361A2 (pt) emplastro de opipramol
CL2014000393A1 (es) Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
EA201400628A1 (ru) Трансдермальная терапевтическая система для введения фентанила или его аналога
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas